Cargando…
HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
BACKGROUND: The production of recombinant monoclonal antibodies in mammalian cell culture is of high priority in research and medical fields. A critical step in this process is the isolation of the antigen-binding domain sequences of antibodies possessing the desired properties. Many different techn...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706699/ https://www.ncbi.nlm.nih.gov/pubmed/26747451 http://dx.doi.org/10.1186/s12896-016-0232-6 |
_version_ | 1782409205490122752 |
---|---|
author | Kivi, Gaily Teesalu, Kaupo Parik, Jüri Kontkar, Elen Ustav, Mart Noodla, Liis Ustav, Mart Männik, Andres |
author_facet | Kivi, Gaily Teesalu, Kaupo Parik, Jüri Kontkar, Elen Ustav, Mart Noodla, Liis Ustav, Mart Männik, Andres |
author_sort | Kivi, Gaily |
collection | PubMed |
description | BACKGROUND: The production of recombinant monoclonal antibodies in mammalian cell culture is of high priority in research and medical fields. A critical step in this process is the isolation of the antigen-binding domain sequences of antibodies possessing the desired properties. Many different techniques have been described to achieve this goal, but all have shortcomings; most techniques have problems with robustness, are time-consuming and costly, or have complications in the transfer from isolation to production phase. Here, we report a novel HybriFree technology for the development of monoclonal antibodies from different species that is robust, rapid, inexpensive and flexible and can be used for the subsequent production of antibodies in mammalian cell factories. RESULTS: HybriFree technology is illustrated herein via detailed examples of isolating mouse, rabbit and chicken monoclonal antibody sequences from immunized animals. Starting from crude spleen samples, antigen capturing of specific B-cells is performed initially. cDNA of antibody variable domains is amplified from the captured cells and used a source material for simple and rapid restriction/ligation free cloning of expression vector library in order to produce scFv-Fc or intact IgG antibodies. The vectors can be directly used for screening purposes as well as for the subsequent production of the developed monoclonal antibodies in mammalian cell culture. The antibodies isolated by the method have been shown to be functional in different immunoassays, including ELISA, immunofluorescence and Western blot. In addition, we demonstrate that by using a modified method including a negative selection step, we can isolate specific antibodies targeting the desired epitope and eliminate antibodies directed to undesired off-targets. CONCLUSIONS: HybriFree can be used for the reliable development of monoclonal antibodies and their subsequent production in mammalian cells. This simple protocol requires neither the culturing of B-cells nor single-cell manipulations, and only standard molecular biology laboratory equipment is needed. In principle, the method is applicable to any species for which antibody cDNA sequence information is available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12896-016-0232-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4706699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47066992016-01-10 HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species Kivi, Gaily Teesalu, Kaupo Parik, Jüri Kontkar, Elen Ustav, Mart Noodla, Liis Ustav, Mart Männik, Andres BMC Biotechnol Methodology Article BACKGROUND: The production of recombinant monoclonal antibodies in mammalian cell culture is of high priority in research and medical fields. A critical step in this process is the isolation of the antigen-binding domain sequences of antibodies possessing the desired properties. Many different techniques have been described to achieve this goal, but all have shortcomings; most techniques have problems with robustness, are time-consuming and costly, or have complications in the transfer from isolation to production phase. Here, we report a novel HybriFree technology for the development of monoclonal antibodies from different species that is robust, rapid, inexpensive and flexible and can be used for the subsequent production of antibodies in mammalian cell factories. RESULTS: HybriFree technology is illustrated herein via detailed examples of isolating mouse, rabbit and chicken monoclonal antibody sequences from immunized animals. Starting from crude spleen samples, antigen capturing of specific B-cells is performed initially. cDNA of antibody variable domains is amplified from the captured cells and used a source material for simple and rapid restriction/ligation free cloning of expression vector library in order to produce scFv-Fc or intact IgG antibodies. The vectors can be directly used for screening purposes as well as for the subsequent production of the developed monoclonal antibodies in mammalian cell culture. The antibodies isolated by the method have been shown to be functional in different immunoassays, including ELISA, immunofluorescence and Western blot. In addition, we demonstrate that by using a modified method including a negative selection step, we can isolate specific antibodies targeting the desired epitope and eliminate antibodies directed to undesired off-targets. CONCLUSIONS: HybriFree can be used for the reliable development of monoclonal antibodies and their subsequent production in mammalian cells. This simple protocol requires neither the culturing of B-cells nor single-cell manipulations, and only standard molecular biology laboratory equipment is needed. In principle, the method is applicable to any species for which antibody cDNA sequence information is available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12896-016-0232-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-08 /pmc/articles/PMC4706699/ /pubmed/26747451 http://dx.doi.org/10.1186/s12896-016-0232-6 Text en © Kivi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Methodology Article Kivi, Gaily Teesalu, Kaupo Parik, Jüri Kontkar, Elen Ustav, Mart Noodla, Liis Ustav, Mart Männik, Andres HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species |
title | HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species |
title_full | HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species |
title_fullStr | HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species |
title_full_unstemmed | HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species |
title_short | HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species |
title_sort | hybrifree: a robust and rapid method for the development of monoclonal antibodies from different host species |
topic | Methodology Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706699/ https://www.ncbi.nlm.nih.gov/pubmed/26747451 http://dx.doi.org/10.1186/s12896-016-0232-6 |
work_keys_str_mv | AT kivigaily hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies AT teesalukaupo hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies AT parikjuri hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies AT kontkarelen hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies AT ustavmart hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies AT noodlaliis hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies AT ustavmart hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies AT mannikandres hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies |